Toxicity and clinical effects of intra-arterial (IA) continuous infusion of recombinant interleukin-2 (rIL-2) were evaluated in twelve patients with low-stage transitional cell carcinoma (TCC) of the bladder (T1NOMO; G1 to G2). rIL-2 dosages were escalated from 18 x 10(3) to 18 x 10(6) IU/m2/d in four groups of three patients. After two 5-day courses, separated by a 48-hour interval, evaluation of clinical response and transurethral resection (TUR) were carried out. World Health Organization (WHO) Grade 3 toxicity occurred in 2 of 12 patients (hypotension/mental confusion and fever, respectively); all side effects rapidly disappeared after infusion was abandoned. No laboratory toxicity developed in any patient. Two pathologically proven complete responses (CR) were achieved using 18 x 10(4) IU/m2/d, and three partial responses (PR) were achieved using 18 x 10(5) IU/m2/d in two patients and 18 x 10(6) IU/m2/d in one patient, giving an overall response rate of 42%. All objective responses are still ongoing after a mean follow-up time of 23 months (range, 12 to 32 months). Local relapses occurred 3 months after TUR only in two nonresponders.
Continuous intra-arterial administration of recombinant interleukin-2 in low-stage bladder cancer: a phase IB study / Tubaro, Andrea; Velotti, F.; Stoppacciaro, Antonella; Santoni, Angela; Vicentini, C.; Bossola, P. C.; Galassi, P.; Pettinato, A.; Morrone, Stefania; Napolitano, T.; Frati, Luigi; Ruco, Luigi; Miano, Lucio; Pourreau, C. N.; Miano, Lucio. - In: CANCER. - ISSN 0008-543X. - STAMPA. - 68:(1991), pp. 56-61. [10.1002/1097-0142(19910701)68:1<56::AID-CNCR2820680111>3.0.CO;2-Z]
Continuous intra-arterial administration of recombinant interleukin-2 in low-stage bladder cancer: a phase IB study.
TUBARO, ANDREA;STOPPACCIARO, ANTONELLA;SANTONI, Angela;MORRONE, Stefania;FRATI, Luigi;RUCO, Luigi;MIANO, Lucio;MIANO, Lucio
1991
Abstract
Toxicity and clinical effects of intra-arterial (IA) continuous infusion of recombinant interleukin-2 (rIL-2) were evaluated in twelve patients with low-stage transitional cell carcinoma (TCC) of the bladder (T1NOMO; G1 to G2). rIL-2 dosages were escalated from 18 x 10(3) to 18 x 10(6) IU/m2/d in four groups of three patients. After two 5-day courses, separated by a 48-hour interval, evaluation of clinical response and transurethral resection (TUR) were carried out. World Health Organization (WHO) Grade 3 toxicity occurred in 2 of 12 patients (hypotension/mental confusion and fever, respectively); all side effects rapidly disappeared after infusion was abandoned. No laboratory toxicity developed in any patient. Two pathologically proven complete responses (CR) were achieved using 18 x 10(4) IU/m2/d, and three partial responses (PR) were achieved using 18 x 10(5) IU/m2/d in two patients and 18 x 10(6) IU/m2/d in one patient, giving an overall response rate of 42%. All objective responses are still ongoing after a mean follow-up time of 23 months (range, 12 to 32 months). Local relapses occurred 3 months after TUR only in two nonresponders.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
